Evotec receives € 3 m milestone payment for Bayer starting Phase II clinical development of DNP programme

  • Evotec SE announced today that the Company received a € 3 m milestone payment from Bayer AG as a result of another promising small molecule from the Evotec-Bayer multi-target research alliance advancing into Phase II clinical development as a potential treatment for diabetic neuropathic pain (“DNP”). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-eur-3-m-milestone-payment-for-bayer-starting-phase-ii-clinical-development-of-dnp-programme-6155

    Du magst vielleicht auch